Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.
about
Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid IntermediatesLipidomics-Reshaping the Analysis and Perception of Type 2 DiabetesMarkers of skeletal muscle mitochondrial function and lipid accumulation are moderately associated with the homeostasis model assessment index of insulin resistance in obese menMondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signalingSphingolipids and phospholipids in insulin resistance and related metabolic disorders.Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content.Increased intramuscular lipid synthesis and low saturation relate to insulin sensitivity in endurance-trained athletes.Bioactives of Artemisia dracunculus L. enhance insulin sensitivity by modulation of ceramide metabolism in rat skeletal muscle cells.Multi-tissue computational modeling analyzes pathophysiology of type 2 diabetes in MKR mice.Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesitySaturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors.Reducing plasma membrane sphingomyelin increases insulin sensitivity.Ceramides and glucosylceramides are independent antagonists of insulin signalingSkeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes?Cellular mechanism of insulin resistance in nonalcoholic fatty liver diseaseCeramides as modulators of cellular and whole-body metabolismHigh-fat load: mechanism(s) of insulin resistance in skeletal muscle.Targeting ceramide synthesis to reverse insulin resistance.Exercise and Weight Loss Improve Muscle Mitochondrial Respiration, Lipid Partitioning, and Insulin Sensitivity After Gastric Bypass Surgery.Skeletal intramyocellular lipid metabolism and insulin resistance.Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implicationsRole of intramyocelluar lipids in human healthIntramuscular lipid metabolism, insulin action, and obesity.Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistanceThe role of skeletal muscle sphingolipids in the development of insulin resistanceEffects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide.Training Does Not Alter Muscle Ceramide and Diacylglycerol in Offsprings of Type 2 Diabetic Patients Despite Improved Insulin Sensitivity.Sphingolipids: the nexus between Gaucher disease and insulin resistance.Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance.Lipids and diabetic retinopathy.Ageing, adipose tissue, fatty acids and inflammation.Lipid-mediated muscle insulin resistance: different fat, different pathways?Targeting ceramide metabolism in obesity.Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss.Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans.Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption.Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients.Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans.Skeletal muscle ceramide species in men with abdominal obesity.
P2860
Q26739957-63D4075C-04E5-4F58-A7A2-D766C937E7A7Q28073169-65B9D73B-74A4-4667-9305-AB8681C94A64Q28533838-CA4FC4A1-0F17-4D11-B9C2-04DA656C2C08Q28828461-8FB9E5EC-DCE4-4FCB-87C7-4AD5CDDEE7DFQ30241943-15AD1FB2-9E17-48E7-AD74-A0A368B6C2B4Q33556682-4DE92CD3-EC34-4FC4-A1B5-F4EC3B55869DQ33841171-D5FF1251-2FBF-4CC9-9E8E-01E7350B12B4Q33849575-6159D211-7212-471F-AC3C-5248F10F76DBQ33910761-F015BF5D-3CF3-4DA7-B6B7-D5DA4DFCF347Q34060303-A79F4E63-9DB6-4954-BA6B-D991906A0ABBQ34132356-BF2F1D84-47DA-4800-B5DC-DB4FD5B0F395Q34208250-F3DBE05D-8646-43B6-AB24-765150A00043Q34384118-38940FE0-5B41-487D-9302-6F3A4B6A3382Q35227175-01E8E9E8-9FA5-4F62-B044-95D7FA1459C6Q35239565-4E3F82E5-39C7-4E21-91FB-EFECF2DD9E25Q35484864-57283299-309D-47FD-A72A-FC5A1093013EQ35688140-F234FDD5-5BF9-46FA-924C-B32D9C8655C9Q35757184-EFA04963-1E9A-44AE-B3E3-3E98E7B80D5FQ36186307-D8F70403-87D3-4444-B8DA-1DCD29A2B26AQ36603044-E565474E-F7B9-41C5-B922-4659B21946D7Q36617551-3A7DCFE6-7464-490B-9C48-8A1BDFE8E8C8Q37007425-9A90C8AE-CDE0-4D26-A03F-9B8D8625744AQ37034193-5987C3D7-E753-47C5-8F94-EBDCAF3E59FEQ37066869-4443C40E-BA25-4BB5-941F-149902517B6BQ37189363-5C1CB850-657B-4FAD-A966-3016ED72F1CCQ37246341-AD3AC96D-56BE-4B02-A5E0-1C4905209484Q37335290-CD4C3CA8-1DB2-41D8-860C-28A3C39FA522Q37799400-D9ADDAFA-7AC2-45AD-A5AE-9AC4E6C5C6E5Q37862117-BC9F68EE-7BA0-483B-819F-4BB79E48EDF6Q37961883-B174F4BB-890D-445B-8956-FC2F210F5FA9Q38264849-A0CB0718-25A3-4E1A-8399-155F9E0496B5Q38537208-FD00DD24-9691-491A-B829-ED8D9FB4CE0FQ38887432-D0A6DC4F-AE5C-43F6-BB6F-F5E61855A426Q39021881-A14C8104-7B45-4874-AA6F-D6E371F63614Q40209806-DD0E2A49-A43E-425C-8738-7D0061B95DEFQ40955387-A8FD23C9-F357-427B-9438-074B7158334FQ41119321-1419FDB0-18AE-4965-ADDB-25DFADDEBAF3Q41182983-316CCEBA-D9C3-4D0D-B8E8-DA00C4B3DE4EQ46589857-63D3A50C-FD66-40DB-9AC9-FAB25FE59745Q46753548-15CDC8BD-A722-4F95-9374-6D18E5199521
P2860
Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@en
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@nl
type
label
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@en
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@nl
prefLabel
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@en
Human skeletal muscle ceramide ...... in muscle insulin sensitivity.
@nl
P2093
P50
P1433
P1476
Human skeletal muscle ceramide ...... in muscle insulin sensitivity
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-008-1014-Z
P577
2008-05-06T00:00:00Z